Sang Cheul Oh

机构：The University of Texas MD Anderson Cancer Center, University of Oregon, Korea University, Korea University Medical Center, Dong-A University Hospital, Oregon Center For Applied Science (United States), Drug Discovery Laboratory (Norway), Korea University, Universidad del Noreste · ORCID：0000-0002-0527-6001

发表论文 400 篇 · 总被引 14210 次 · h-index 49

代表论文

• Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study (2025 · Journal of Clinical Oncology · 被引 44)
• Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 18)
• Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma (2025 · Clinical Cancer Research · 被引 4)
• LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 study (2025 · Annals of Oncology · 被引 4)
• Applying Computational Protein Design to Engineer Affibodies for Affinity-controlled Delivery of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor (2025 · Biomacromolecules · 被引 4)
• Nivolumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4) (2025 · Cancer Research and Treatment · 被引 3)